Immutep (IMMP) 6-K: FDA Project Optimus requirements completed

Immutep Limited furnished a Form 6-K reporting an exhibit titled “Immutep Announces Successful Completion of FDA Project Optimus Requirements.” The notice identifies Exhibit 99.1 as the related material and is dated October 13, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Immutep Limited furnished a Form 6-K reporting an exhibit titled “Immutep Announces Successful Completion of FDA Project Optimus Requirements.” The notice identifies Exhibit 99.1 as the related material and is dated October 13, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immutep (IMMP) announce in this Form 6-K?

Immutep announced the successful completion of FDA Project Optimus requirements, as described in Exhibit 99.1.

What is included as Exhibit 99.1 in the filing?

Exhibit 99.1 is titled “Immutep Announces Successful Completion of FDA Project Optimus Requirements.”

When was the Form 6-K dated?

The Form 6-K is dated October 13, 2025.

What is Immutep’s Commission File Number?

The Commission File Number is 001-35428.

What type of SEC filing is this for Immutep (IMMP)?

This is a Form 6-K, a report of a foreign private issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/14/2025 - 06:02 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as October 13, 2025

Commission File Number 001-35428

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

EXHIBIT INDEX


Exhibit		Description of Exhibit

99.1		Immutep Announces Successful Completion of FDA Project Optimus Requirements

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 13, 2025


IMMUTEP LIMITED

By:		/s/ Marc Voigt
Name:		Marc Voigt
Title:		Chief Executive Officer

Source: View Original Filing on SEC EDGAR